Market Overview

UPDATE: Jefferies Raises PT to $10 on Amedisys, Maintains Neutral on Reimbursement Uncertainty

Share:
Related AMED
Oppenheimer Upgrades Amedisys To Outperform, Sets $40 Target
Benzinga's Top Upgrades
Healthcare ratings roundup (Seeking Alpha)

Jefferies maintained Amedisys (NASDAQ: AMED) with a Hold and raised the price target from $9.00 to $10.00.

Jefferies analyst Brian Tanquilut wrote, "We continue to have a cautious view on AMED given our belief that ongoing budget discussions in DC could yield incremental rate cuts for home nursing providers such as AMED. Additionally, we are concerned that ongoing volume pressure (from persistent weakness in recertifications) will impact AMED's ability to offset upcoming rate cuts and drive LT EPS growth."

Amedisys closed at $11.19 on Wednesday.

Latest Ratings for AMED

DateFirmActionFromTo
Feb 2016OppenheimerUpgradesPerformOutperform
Jan 2016Mizuho SecuritiesUpgradesNeutralBuy
Jan 2016BairdMaintainsNeutral

View More Analyst Ratings for AMED
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMED)

Get Benzinga's Newsletters